A period of immobility after remifentanil administration protects from nausea: an experimental randomized cross-over study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00010667

Enrollment

Registered

2016-06-20

Start date

2013-07-08

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

opioid-induced nausea and vomiting

Interventions

Group 1: All participants lay in a semirecumbent position and receive infusion of remifentanil (0,15µg/kg/min) for 30 minutes. After stopping the infusion, a standardized movement intervention took pl

Eligibility

Sex/Gender

Female

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Healthy women

Exclusion criteria

Exclusion criteria: Smoking, chronic deseases, vertigo

Design outcomes

Primary

Measure	Time frame
Incidence of nausea and vomiting, assessed on a 10-step numerical rating scale. The times for this assessment were (1) prior to remifentanil infusion, (2) briefly before ending remifentanil infusion, and (3) after the movement interventions.	—

Countries

Germany

Contacts

Public ContactFabian Heuser

Klinikum rechts der Isar, Technische Universität München

fabian.heuser@me.com08941404291

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 1, 2026